Study guide

8.2 Pediatric Heart Failure & Cardiomyopathies

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

8.2 Pediatric Heart Failure & Cardiomyopathies

Key Takeaways Explain This Topic AI

Pediatric heart failure exhibits distinct developmental pathophysiology: neonatal and infant myocardium contains only 30% organized contractile myofibrils (vs. 60% in adults), lacks Frank-Starling compliance reserve, and relies predominantly on heart rate and extracellular calcium influx to augment cardiac output.

Large left-to-right shunts (VSD, large PDA) present with congestive heart failure between 2 and 8 weeks of life, coinciding with the physiological drop in pulmonary vascular resistance (PVR) that massively increases pulmonary blood flow.

Captopril is the preferred ACE inhibitor for initial titration in neonates and young infants due to its short half-life (1–2 hours), starting at 0.05–0.1 mg/kg/dose oral three times daily and titrating to 0.5–2 mg/kg/dose TID, while monitoring serum creatinine and potassium.

Digoxin maintains a narrow therapeutic range in pediatric heart failure of 0.5–0.9 ng/mL (levels >1.0–1.2 ng/mL lack therapeutic benefit while escalating cardiotoxicity); hypokalemia strongly potentiates digoxin toxicity by increasing myocardial receptor binding.

Sacubitril/valsartan is FDA-approved down to 1 year of age for pediatric heart failure with left ventricular systolic dysfunction; switching from an ACE inhibitor requires a mandatory 36-hour washout period to prevent bradykinin-mediated fatal angioedema.

Last updated: September 2026

8.2 Pediatric Heart Failure & Cardiomyopathies

Heart failure (HF) in pediatric patients is a clinical and pathophysiological syndrome characterized by the inability of the heart to deliver an adequate supply of oxygenated blood to metabolizing tissues, or the ability to do so only at abnormally elevated ventricular filling pressures. Unlike adult heart failure, which is predominantly driven by ischemic coronary artery disease, chronic hypertension, and age-related degenerative changes, pediatric heart failure arises from a heterogeneous spectrum of congenital structural heart defects, primary cardiomyopathies, myocarditis, and systemic metabolic insults.

Developmental Myocardial Physiology & Pediatric Pathophysiology

The immature myocardium possesses unique ultrastructural and mechanical characteristics that limit its adaptive reserve during hemodynamic stress:

Myofibrillar Architecture: Immature neonatal myocytes contain only 30% organized contractile elements (myofibrils) and 70% non-contractile mass (nuclei, cytoplasm, mitochondria), compared to 60% contractile myofibrils in mature adult myocytes.

Reduced Ventricular Compliance: The neonatal heart has high stiffness and poor passive diastolic distensibility. Consequently, it operates near the peak of its Frank-Starling curve under resting conditions. Volume loading (preload expansion) yields minimal increase in stroke volume ( S V SV S V ) while rapidly driving ventricular end-diastolic pressures into pulmonary venous congestion.

Heart Rate Dependency: Because stroke volume is relatively fixed by low compliance and myofibrillar immaturity, cardiac output ( C O = H R × S V CO = HR \times SV CO = H R × S V ) is critically dependent on heart rate . Severe bradycardia causes immediate circulatory collapse, whereas sustained extreme tachycardia ( > 200 bpm > 200\text{ bpm} > 200 bpm ) curtails diastolic filling time and induces ischemia.

Excitation-Contraction Coupling: Immature myocytes have a rudimentary, disorganized sarcoplasmic reticulum (SR) and lack a well-developed transverse tubule ( T T T -tubule) invagination network. Intracellular calcium recycling is inefficient. The neonatal heart relies heavily upon extracellular calcium influx via sarcolemmal L L L -type calcium channels for contraction. Acute systemic hypocalcemia rapidly causes profound electromechanical uncoupling and cardiogenic shock. Developmental Differences: Immature vs Adult Myocardium

  • ┌───────────────────────────────┬───────────────────────────────┬───────────────────────────────┐
  • │ Ultrastructural Feature │ Neonate / Infant │ Older Child / Adult │
  • ├───────────────────────────────┼───────────────────────────────┼───────────────────────────────┤
  • │ Contractile Myofibril Fraction│ ~30% of cell volume │ ~60% of cell volume │
  • │ Ventricular Compliance │ Stiff, non-compliant │ Compliant, distensible │
  • │ Frank-Starling Reserve │ Minimal (flat curve) │ Substantial reserve │
  • │ Determinant of Cardiac Output │ Heart rate dependent │ Stroke volume & heart rate │
  • │ Sarcoplasmic Reticulum │ Immature, rudimentary │ Dense, highly organized │
  • │ Calcium Source for Systole │ Extracellular trans-sarcolemmal│ Intracellular SR stores (CICR)│
  • └───────────────────────────────┴───────────────────────────────┴───────────────────────────────┘
  • Etiological Spectrum of Pediatric Heart Failure
  • 1. Left-to-Right Congenital Shunts (Pulmonary Overcirculation)

In defects characterized by non-cyanotic left-to-right communications—such as large ventricular septal defects (VSD) , patent ductus arteriosus (PDA) , and complete atrioventricular septal defects (AVSD) —congestive heart failure does not manifest at birth. In utero and during the first week of life, high pulmonary vascular resistance matches systemic vascular resistance, limiting shunt volume. Between 2 and 8 weeks of life , physiological regression of the pulmonary arteriolar smooth muscle media occurs, precipitating a steep drop in PVR.

As PVR falls, systemic arterial blood preferentially diverts across the defect into the low-resistance pulmonary circulation. This produces massive pulmonary overcirculation ( Q p : Q s > 2 : 1 to 3 : 1 Q_p:Q_s > 2:1\text{ to }3:1 Q p ​ : Q s ​ > 2 : 1 to 3 : 1 ) and left-sided chamber volume overload. Clinically, infants present between 1 and 2 months of age with:

Feeding Intolerance: Poor feeding, prolonged feeding duration ( > 30 minutes > 30\text{ minutes} > 30 minutes ), and failure to finish bottles ("eating is the infant's stress test").

Diaphoresis: Sympathetic hyperactivation causing profound head sweating during feeds.

Tachypnea & Retractions: Intercostal retractions, grunting, and persistent crackles.

Failure to Thrive: Caloric expenditure on the work of breathing exceeds intake, resulting in severe weight gain faltering (dropping across percentiles on growth charts).

2. Dilated Cardiomyopathy (DCM)

DCM represents the most common pediatric cardiomyopathy, characterized by left ventricular chamber dilation and impaired systolic function ( E F < 45 % EF < 45\% EF < 45% , fractional shortening < 25 % < 25\% < 25% ). Etiologies include:

Viral Myocarditis: Enteroviruses (coxsackievirus B), adenovirus, parvovirus B19, human herpesvirus 6, and SARS-CoV-2. Acute autoimmune-mediated myocyte necrosis leads to acute decompensated shock or chronic dilated cardiomyopathy.

Genetic & Familial: Mutations in sarcomeric genes ( TTN , MYH7 ), cytoskeletal proteins ( DMD dystrophin in Duchenne and Becker muscular dystrophy), and mitochondrial respiratory chain enzymes.

Anthracycline Cardiotoxicity: Chemotherapeutic agents (doxorubicin, daunorubicin) induce dose-dependent, progressive free-radical myocardial damage. Lifetime cumulative doses > 300 mg/m 2 > 300\text{ mg/m}^2 > 300 mg/m 2 significantly amplify late cardiomyopathy risks.

3. Hypertrophic Cardiomyopathy (HCM)

Characterized by disproportionate myocardial hypertrophy, myofibrillar disarray, and diastolic dysfunction, often with left ventricular outflow tract (LVOT) obstruction. Causes include autosomal dominant sarcomeric mutations ( MYH7 , MYBPC3 ), Rasopathies ( Noonan syndrome with PRKAG2 mutations), metabolic storage disorders ( Pompe disease / glycogen storage disease type II), and infants of diabetic mothers (IDM) . In IDM, fetal hyperinsulinism stimulates glycogen and fat deposition in the interventricular septum; this condition is self-limiting, typically resolving over 3 to 6 months post-delivery as maternal glucose exposure ceases.

Neurohormonal Maladaptation in Children

Similar to adults, pediatric cardiac dysfunction triggers compensatory neurohormonal cascades that become maladaptive:

Sympathetic Nervous System (SNS): Baroreceptor uncoupling drives chronic elevations in circulating epinephrine and norepinephrine, producing sinus tachycardia, increased myocardial oxygen demand, peripheral vasoconstriction, and progressive down-regulation/desensitization of cardiac β 1 \beta_1 β 1 ​ -adrenergic receptors.

Renin-Angiotensin-Aldosterone System (RAAS): Diminished renal perfusion pressure prompts juxtaglomerular renin release. Angiotensin II induces intense arteriolar vasoconstriction (increasing systemic afterload and impeding forward cardiac output) and stimulates cellular hypertrophy and apoptosis. Aldosterone drives sodium and water retention in the distal nephron, exacerbating pulmonary edema and myocardial interstitial fibrosis.

Natriuretic Peptides: Ventricular wall stress triggers cardiac secretion of B-type Natriuretic Peptide (BNP) and its biologically inert fragment, N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) . These biomarkers are elevated in pediatric heart failure and assist in differentiating cardiac pulmonary overcirculation from primary viral bronchiolitis.

Comprehensive Pharmacotherapy of Pediatric Heart Failure Pediatric Heart Failure Pharmacotherapy Roadmap

  • [Congestion & Volume Overload] [Afterload Reduction & Neurohormonal]
  • │ │
  • ▼ ▼
  • ┌──────────────────┐ ┌───────────────────────┐
  • │ Diuretics │ │ RAAS Antagonists │
  • └─────────┬────────┘ └──────────┬────────────┘
  • │ │
  • Furosemide (1-2 mg/kg/dose) • Captopril (0.05-0.1 mg/kg/dose)
  • Chlorothiazide (10-20 mg/kg BID) • Enalapril (0.1 mg/kg/day)
  • Spironolactone (1-3 mg/kg/day) • Sacubitril/Valsartan (ARNI)
  • │ │
  • └────────────────────┬────────────────────┘
  • │
  • ▼
  • ┌───────────────────────────┐
  • │ Long-Term Remodeling │
  • └─────────────┬─────────────┘
  • │
  • Carvedilol (0.05-0.1 mg/kg BID)
  • Metoprolol Succinate
  • Digoxin (0.5-0.9 ng/mL target)

Drug Class & Agent Pediatric Starting Dose Target Maintenance Dose Primary Mechanism & Site Key Toxicities & Monitoring Parameters

Loop Diuretic: Furosemide 1 to 2 mg/kg/dose 1\text{ to }2\text{ mg/kg/dose} 1 to 2 mg/kg/dose PO or IV q6–12h 1 to 4 mg/kg/day 1\text{ to }4\text{ mg/kg/day} 1 to 4 mg/kg/day (oral bioavailability ≈ 50 % \approx 50\% ≈ 50% ) Inhibits Na + / K + / 2 Cl − \text{Na}^+/\text{K}^+/2\text{Cl}^- Na + / K + /2 Cl − symporter in thick ascending limb of Henle Hypokalemia, hypochloremia, metabolic alkalosis, prerenal azotemia, hypercalciuria with nephrocalcinosis in neonates; ototoxicity with rapid IV boluses.

Thiazide Diuretic: Chlorothiazide 10 to 20 mg/kg/dose 10\text{ to }20\text{ mg/kg/dose} 10 to 20 mg/kg/dose PO BID (or 2 – 5 mg/kg/dose 2\text{--}5\text{ mg/kg/dose} 2 – 5 mg/kg/dose IV q12h) Max 40 mg/kg/day 40\text{ mg/kg/day} 40 mg/kg/day (PO) or 1 ,000 mg/day 1\text{,000 mg/day} 1 ,000 mg/day Inhibits Na + / Cl − \text{Na}^+/\text{Cl}^- Na + / Cl − cotransporter in distal convoluted tubule; sequential nephron blockade Synergistic volume depletion; profound hypokalemia, hyponatremia, hyperuricemia. Monitor electrolytes closely.

Aldosterone Antagonist: Spironolactone 1 to 3 mg/kg/day 1\text{ to }3\text{ mg/kg/day} 1 to 3 mg/kg/day PO divided daily or BID Up to 3 – 4 mg/kg/day 3\text{--}4\text{ mg/kg/day} 3 – 4 mg/kg/day (max 100 mg/day 100\text{ mg/day} 100 mg/day ) Competitively antagonizes mineralocorticoid receptors in cortical collecting tubule; antifibrotic Hyperkalemia, gynecomastia. Monitor potassium and SCr; caution when co-administered with ACEI or ARNI.

Short-Acting ACEI: Captopril 0.05 to 0.1 mg/kg/dose 0.05\text{ to }0.1\text{ mg/kg/dose} 0.05 to 0.1 mg/kg/dose PO TID (infants) Titrate every 1–2 days to 0.5 to 2 mg/kg/dose 0.5\text{ to }2\text{ mg/kg/dose} 0.5 to 2 mg/kg/dose PO TID (max 6 mg/kg/day 6\text{ mg/kg/day} 6 mg/kg/day ) Inhibits conversion of Ang I to Ang II; reduces SVR without reflex tachycardia First-line in neonates/infants due to short t 1 / 2 t_{1/2} t 1/2 ​ (1–2 h); hypotension, acute kidney injury, hyperkalemia, cough, angioedema.

Long-Acting ACEI: Enalapril 0.1 mg/kg/day 0.1\text{ mg/kg/day} 0.1 mg/kg/day PO divided daily or BID Titrate every 1–2 weeks to 0.5 mg/kg/day 0.5\text{ mg/kg/day} 0.5 mg/kg/day (max 40 mg/day 40\text{ mg/day} 40 mg/day ) Prodrug bioactivated to enalaprilat; ACE inhibition Preferred in stable older infants and children; monitor BP, SCr, BUN, serum potassium.

Beta-Blocker: Carvedilol 0.05 to 0.1 mg/kg/dose 0.05\text{ to }0.1\text{ mg/kg/dose} 0.05 to 0.1 mg/kg/dose PO BID Titrate q2 weeks to 0.4 to 0.5 mg/kg/dose 0.4\text{ to }0.5\text{ mg/kg/dose} 0.4 to 0.5 mg/kg/dose PO BID (max 25 mg 25\text{ mg} 25 mg BID or 50 mg 50\text{ mg} 50 mg BID if > 85 kg > 85\text{ kg} > 85 kg ) Non-selective β 1 , β 2 \beta_1, \beta_2 β 1 ​ , β 2 ​ blockade + α 1 \alpha_1 α 1 ​ blockade; antioxidant and antifibrotic Only initiate in compensated, euvolemic HF ; bradycardia, bronchospasm, acute decompensation, dizziness.

Inotrope / Neurohormonal: Digoxin Oral maintenance: 8 to 10 mcg/kg/day 8\text{ to }10\text{ mcg/kg/day} 8 to 10 mcg/kg/day divided BID (infants); 5 to 8 mcg/kg/day 5\text{ to }8\text{ mcg/kg/day} 5 to 8 mcg/kg/day divided daily or BID (children) Target serum trough: 0.5 to 0.9 ng/mL 0.5\text{ to }0.9\text{ ng/mL} 0.5 to 0.9 ng/mL Inhibits Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase; neurohormonal modulation; vagomimetic slowing of AV node Arrhythmias, vomiting, feeding intolerance, halos; hypokalemia markedly potentiates toxicity . Narrow index.

ARNI: Sacubitril / Valsartan Weight-tiered dosing: < 40 kg < 40\text{ kg} < 40 kg : 1.6 to 3.1 mg/kg/dose 1.6\text{ to }3.1\text{ mg/kg/dose} 1.6 to 3.1 mg/kg/dose BID; ≥ 40 kg \ge 40\text{ kg} ≥ 40 kg : adult doses ( 24 / 26 mg 24/26\text{ mg} 24/26 mg to 97 / 103 mg 97/103\text{ mg} 97/103 mg BID) Titrate q2–4 weeks to target maintenance band Neprilysin inhibitor + Angiotensin II Receptor Blocker Approved ≥ 1 year \ge 1\text{ year} ≥ 1 year ; hypotension, hyperkalemia, renal impairment; mandatory 36-hour washout from ACE inhibitors .

Diuretic Management Pearls

Loop Diuretics: Furosemide is the initial agent for relieving pulmonary congestion and peripheral edema. Chronic high-dose use in preterms and neonates induces hypercalciuria, precipitating renal medullary nephrocalcinosis and osteopenia. Renal ultrasounds should monitor chronic neonatal therapy.

Sequential Nephron Blockade: When chronic loop diuretic therapy causes hypertrophy of the distal convoluted tubule and compensatory sodium reabsorption (diuretic resistance), adding oral chlorothiazide ( 10 to 20 mg/kg/dose 10\text{ to }20\text{ mg/kg/dose} 10 to 20 mg/kg/dose BID) produces synergistic, potent natriuresis. Potassium wasting is amplified, mandating aggressive potassium chloride supplementation.

Aldosterone Antagonism: Spironolactone provides mild kaliuresis-sparing diuresis while preventing aldosterone-induced myocardial fibrosis. It is standard in pediatric dilated cardiomyopathy.

ACE Inhibitors: Dosing & Clinical Rules

Captopril as the Titration Benchmark: In neonates, young infants, and hospitalized children with tenuous hemodynamics, captopril is the ACE inhibitor of choice. Because of its rapid onset and short half-life ( 1 to 2 hours ), any catastrophic hypotension or precipitous drop in glomerular filtration can be reversed rapidly by withholding the drug. In contrast, long-acting agents like enalaprilat or lisinopril have prolonged durations of action (24 to 36 hours) that can prolong renal failure.

Laboratory Monitoring Thresholds: Obtain serum creatinine (SCr), blood urea nitrogen (BUN), and serum potassium at baseline and 1 to 2 weeks following initiation or dose escalation.

An acute SCr increase of up to 30% above baseline is acceptable and reflects hemodynamic efferent arteriolar vasodilation rather than structural tubular injury.

If SCr rises > 30 % > 30\% > 30% or serum potassium exceeds 5.5 mEq/L 5.5\text{ mEq/L} 5.5 mEq/L , reduce the dose, evaluate intravascular volume status, and reassess concomitant medications (NSAIDs, spironolactone).

Beta-Adrenergic Blockade Principles

Initiation Criteria: Beta-blockers ( carvedilol or metoprolol succinate ) must be started only when the patient is clinically stable, compensated, and euvolemic . Initiating beta-blockade during acute decompensated shock unmasks acute left ventricular failure, worsening cardiogenic collapse.

"Start Low, Go Slow": Begin carvedilol at 0.05 to 0.1 mg/kg/dose 0.05\text{ to }0.1\text{ mg/kg/dose} 0.05 to 0.1 mg/kg/dose twice daily. Double the dose no more frequently than every 2 weeks , monitoring heart rate, blood pressure, and clinical signs of worsening fluid retention. Target doses ( 0.4 to 0.5 mg/kg/dose 0.4\text{ to }0.5\text{ mg/kg/dose} 0.4 to 0.5 mg/kg/dose BID) confer optimal anti-remodeling benefits.

Digoxin: Narrow Therapeutic Index & Pediatric Toxicity

Digoxin exerts positive inotropy by reversibly inhibiting the sarcolemmal Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump , elevating intracellular sodium, which in turn drives the Na + / Ca 2 + \text{Na}^+/\text{Ca}^{2+} Na + / Ca 2 + exchanger to pump calcium into the cytosol. More importantly in heart failure, it exerts neurohormonal suppression, reducing sympathetic outflow and enhancing parasympathetic tone.

Target Serum Concentration: In pediatric heart failure, the therapeutic serum concentration is strictly 0.5 to 0.9 ng/mL 0.5\text{ to }0.9\text{ ng/mL} 0.5 to 0.9 ng/mL . Serum levels > 1.0 to 1.2 ng/mL > 1.0\text{ to }1.2\text{ ng/mL} > 1.0 to 1.2 ng/mL do not confer additional hemodynamic benefit and dramatically increase the risk of lethal proarrhythmia and mortality.

Sampling Timing: Serum levels must be drawn at steady state at least 6 to 8 hours post-dose (preferably immediately prior to the next scheduled dose as a trough) to avoid elevated concentrations during the tissue distribution phase.

Potentiating Factors for Toxicity:

Hypokalemia ( K + < 3.5 mEq/L K^+ < 3.5\text{ mEq/L} K + < 3.5 mEq/L ): Extracellular potassium competes with digoxin for binding to the Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump. Hypokalemia leaves more binding sites available, markedly intensifying digoxin effect and precipitating fatal ventricular arrhythmias even when serum digoxin levels are "normal" (e.g., 0.8 ng/mL 0.8\text{ ng/mL} 0.8 ng/mL ).

Hypomagnesemia & Hypercalcemia: Augment intracellular calcium overload, triggering triggered activity and delayed afterdepolarizations.

Renal Impairment: Digoxin is 70% to 80% eliminated unchanged via glomerular filtration; declining GFR causes rapid drug accumulation.

Clinical Signs of Toxicity: Gastrointestinal symptoms (nausea, non-bilious vomiting, anorexia, poor feeding in infants), neurological signs (lethargy, blurred or xanthopsic [yellow-green] vision), and cardiac arrhythmias (sinus bradycardia, PR prolongation, high-grade AV block, junctional escape rhythms, premature ventricular contractions, bidirectional ventricular tachycardia).

Antidotal Reversal: Administer Digoxin Immune Fab (DigiFab) for life-threatening arrhythmias, marked hyperkalemia ( K + > 5.5 – 6.0 mEq/L K^+ > 5.5\text{--}6.0\text{ mEq/L} K + > 5.5 – 6.0 mEq/L in acute overdose), or ingestion of > 0.3 mg/kg > 0.3\text{ mg/kg} > 0.3 mg/kg in children.

Sacubitril/Valsartan (Entresto) in Pediatric Patients

Sacubitril/valsartan is an Angiotensin Receptor-Neprilysin Inhibitor (ARNI) . Sacubitril is a prodrug whose active metabolite (sacubitrilat) inhibits neprilysin , preventing the degradation of endogenous vasoactive peptides (atrial natriuretic peptide, BNP, bradykinin, adrenomedullin), promoting natriuresis, vasodilation, and antifibrotic signaling. Valsartan selectively blocks the angiotensin II type 1 ( A T 1 AT_1 A T 1 ​ ) receptor .

FDA Indication: Approved for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older (supported by the global PANORAMA-HF clinical trial).

Pediatric Formulations & Dosing: Administered as an extemporaneously compounded or commercially manufactured oral suspension for children weighing < 40 kg < 40\text{ kg} < 40 kg (tiered weight-band dosing starting at 1.6 mg/kg/dose 1.6\text{ mg/kg/dose} 1.6 mg/kg/dose BID and titrating to 3.1 mg/kg/dose 3.1\text{ mg/kg/dose} 3.1 mg/kg/dose BID), or as tablets in older children ≥ 40 kg \ge 40\text{ kg} ≥ 40 kg (starting at 24 / 26 mg 24/26\text{ mg} 24/26 mg or 49 / 51 mg 49/51\text{ mg} 49/51 mg BID, titrating to 97 / 103 mg 97/103\text{ mg} 97/103 mg BID).

The Critical 36-Hour Washout Rule:

Caution

When switching a pediatric patient from an ACE inhibitor (captopril, enalapril, lisinopril) to sacubitril/valsartan, a mandatory 36-hour washout period must elapse between the last dose of the ACE inhibitor and the first dose of sacubitril/valsartan. Both ACE and neprilysin degrade bradykinin . Simultaneous inhibition results in massive bradykinin accumulation, causing catastrophic, life-threatening angioedema of the airway and facial tissues. When switching from an ARB, a washout period is not required.

Practice Pearls & BCPPS Exam Traps

Exam Trap 1: Never administer an ACE inhibitor or ARNI without verifying baseline serum creatinine and potassium, and never co-prescribe potassium-sparing diuretics without a defined electrolyte monitoring schedule.

Exam Trap 2: Digoxin therapeutic levels in heart failure are 0.5 to 0.9 ng/mL 0.5\text{ to }0.9\text{ ng/mL} 0.5 to 0.9 ng/mL , NOT the older adult antiarrhythmic target of 0.8 to 2.0 ng/mL 0.8\text{ to }2.0\text{ ng/mL} 0.8 to 2.0 ng/mL . High-normal levels in infants receiving furosemide risk fatal arrhythmias.

Board Rule: Large left-to-right shunts present with heart failure between 2 and 8 weeks of life , exactly matching the timeline of falling pulmonary vascular resistance. If a 3-day-old infant presents in shock, suspect ductal-dependent congenital heart disease or sepsis, not uncomplicated VSD pulmonary overcirculation.